XERS vs LNTH

For growth investors, Xeris Biopharma Holdings, Inc.

(XERS) is the stronger pick with 43. 7% revenue growth year-over-year, versus 0. 5% for Lantheus Holdings, Inc. (LNTH). Lantheus Holdings, Inc. (LNTH) offers the better valuation at 25. 3x trailing P/E (16. 6x forward), making it the more compelling value choice. Analysts rate Xeris Biopharma Holdings, Inc. (XERS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Lantheus Holdings, Inc.

(LNTH) is the cheapest at 25. 3x versus Xeris Biopharma Holdings, Inc. at 1990. 6x. On forward P/E, Lantheus Holdings, Inc. is actually cheaper at 16. 6x.

Over the past 5 years, Lantheus Holdings, Inc.

(LNTH) delivered a total return of +290. 0%, compared to +87. 9% for Xeris Biopharma Holdings, Inc. (XERS). Over 10 years, the gap is even starker: LNTH returned +40. 0% versus XERS's -68. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lantheus Holdings, Inc.

(LNTH) is the lower-risk stock at 0. 47β versus Xeris Biopharma Holdings, Inc. 's 1. 04β — meaning XERS is approximately 122% more volatile than LNTH relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 3% for Xeris Biopharma Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Xeris Biopharma Holdings, Inc.

(XERS) is pulling ahead at 43. 7% versus 0. 5% for Lantheus Holdings, Inc. (LNTH). On earnings-per-share growth, the picture is similar: Xeris Biopharma Holdings, Inc. grew EPS 100. 9% year-over-year, compared to -21. 8% for Lantheus Holdings, Inc.. Over a 3-year CAGR, XERS leads at 38. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Lantheus Holdings, Inc.

(LNTH) is the more profitable company, earning 15. 2% net margin versus 0. 2% for Xeris Biopharma Holdings, Inc. — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNTH leads at 20. 2% versus 8. 5% for XERS. At the gross margin level — before operating expenses — XERS leads at 81. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Lantheus Holdings, Inc.

(LNTH) trades at 16. 6x forward P/E versus 53. 1x for Xeris Biopharma Holdings, Inc. — 36. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for XERS: 41. 3% to $9. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Lantheus Holdings, Inc.

(LNTH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 47)). Both have compounded well over 10 years (LNTH: +40. 0%, XERS: -68. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: XERS is a small-cap high-growth stock; LNTH is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.